DM
Therapeutic Areas
Novo Nordisk Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Wegovy HD (semaglutide 7.2mg) | Obesity | Approved |
| Awiqli® | Type 2 Diabetes | Approved |
| UBT251 (Triple Agonist) | Type 2 Diabetes | Phase 2 |
| CagriSema (Subcutaneous) | Obesity, Type 2 Diabetes | Phase 3 |
| Oral CagriSema | Obesity, Type 2 Diabetes | Phase 2 |
| Subcutaneous Zenagamtide | Obesity, Diabetes | Phase 2 |
| Amycretin (Subcutaneous) | Obesity | Phase 2 |
| Oral Amycretin | Obesity | Phase 2 |
Leadership Team at Novo Nordisk
LF
Lars Fruergaard Jørgensen
President and Chief Executive Officer
KM
Karsten Munk Knudsen
Executive Vice President & Chief Financial Officer
MS
Marcus Schindler
EVP Research & Early Development, Chief Scientific Officer
MH
Martin Holst Lange
Executive Vice President, Development
HW
Henrik Wulff
Executive Vice President, Product Supply, Quality & IT
CS
Camilla Sylvest
Executive Vice President, Commercial Strategy & Corporate Affairs
DL
Doug Langa
Executive Vice President, North America Operations & President of Novo Nordisk Inc.
MD
Mike Doustdar
Executive Vice President, International Operations
LH
Ludovic Helfgott
Executive Vice President, Rare Disease